Biblio Discovery — Demo Discovery Service

65 results for "Yashdeep Gupta"

Showing 1–20 · 0.89 seconds · RSS

  1. Journal Article

    Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment

    Anu Gupta; Yashdeep Gupta

    Indian Journal of Endocrinology and Metabolism, Vol. 17 No. 5 · 2013 · English · DOAJ Scopus

    Glucocorticoid-induced myopathy is the most common type of drug-induced myopathy. Nearly 60% of patients with Cushing′s syndrome have muscle weakness. Glucocorticoid-induced muscle atrophy affects mainly fast-twitch glycolytic muscle fibers (type IIb fibers). This brief review will discuss the…

  2. Journal Article

    Continuous subcutaneous insulin infusion versus multiple dose insulin

    Yashdeep Gupta; Sanjay Kalra

    Sri Lanka Journal of Diabetes Endocrinology and Metabolism, Vol. 4 No. 1 · 2014 · English · DOAJ

    Continuous subcutaneous insulin infusion (CSII), also known as insulin pump therapy and multiple dose insulin (MDI) are the two main intensified insulin regimens that have been used to achieve strict glycaemic control in patients with diabetes mellitus, especially with type 1 diabetes (T1DM). Each…

  3. Journal Article

    Insulin technique

    Sanjay Kalra; Yashdeep Gupta

    Sri Lanka Journal of Diabetes Endocrinology and Metabolism, Vol. 5 No. 2 · 2015 · English · DOAJ

    Insulin is an important treatment modality of treating diabetes and insulin technique; is a vital component of the insulin prescription and of diabetes care. A thorough knowledge regarding insulin preparations, devices, injecting techniques and the problems encountered with insulin use are…

  4. Journal Article

    Essential Medicines for Children: An Endocrine Perspective

    Sanjay Kalra; Yashdeep Gupta

    International Journal of Health Policy and Management, Vol. 3 No. 6 · 2014 · English · DOAJ Scopus

    The emergence of endocrine disease has created significant challenges for healthcare policy-makers and payers across the world. Policy-makers have to ensure availability of drugs used for various endocrinopathies. One way in which this is facilitated is through the World Health Organization (WHO)…

  5. Journal Article

    Vitiligo, hypothyroidism and cardiomyopathy

    Yashdeep Gupta; Ariachery C Ammini

    Indian Journal of Endocrinology and Metabolism, Vol. 16 No. 3 · 2012 · English · DOAJ Scopus

    Vitiligo in association with autoimmune endocrine disorders, especially with hypothyroidism, is not uncommon. Some amount of pericardial effusion is usually present in long-standing/untreated hypothyroidism. Here we describe the case of young male with, long-standing progressive vitiligo…

  6. Journal Article

    Insulin-derived amyloidosis

    Yashdeep Gupta; Gaurav Singla; Rajiv Singla

    Indian Journal of Endocrinology and Metabolism, Vol. 19 No. 1 · 2015 · English · DOAJ Scopus

    Amyloidosis is the term for diseases caused by the extracellular deposition of insoluble polymeric protein fibrils in tissues and organs. Insulin-derived amyloidosis is a rare, yet significant complication of insulin therapy. Insulin-derived amyloidosis at injection site can cause poor glycemic…

  7. Journal Article

    Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions

    Sanjay Kalra; Yashdeep Gupta; Shiva Patil

    Indian Journal of Endocrinology and Metabolism, Vol. 19 No. 3 · 2015 · English · DOAJ Scopus

    The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of glucose-lowering drugs which act by inhibiting the reabsorption of filtered glucose from the kidneys. Their effect on insulin and glucagon levels has recently been studied but is not fully explained. This communication…

  8. Journal Article

    Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis

    Sanjay Kalra; Rakesh Sahay; Yashdeep Gupta

    Indian Journal of Endocrinology and Metabolism, Vol. 19 No. 4 · 2015 · English · DOAJ Scopus

    Sodium glucose transporter 2 (SGLT2) inhibitors are a recently developed class of drug that have been approved for use in type 2 diabetes. Their unique extra-pancreatic glucuretic mode of action has encouraged their usage in type 1 diabetes as well. At the same time, reports of pseudo ketoacidosis…